Merck & Co Inc

NYSE:MRK   3:59:58 PM EDT
81.07
+1.58 (+1.99%)
4:59:54 PM EDT: $81.10 +0.03 (+0.04%)
Products, Strategic Combinations, Other Pre-Announcement

Gilead And Merck Announce Agreement To Jointly Develop And Commercialize Long-Acting, Investigational Treatment Combinations Of Lenacapavir And Islatravir In Hiv

Published: 03/15/2021 11:07 GMT
Merck & Co Inc (MRK) - Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in Hiv.
Gilead Sciences Inc - Collaboration to Focus on Oral and Injectable Formulations of Lenacapavir and Islatravir.
Gilead Sciences Inc - First Clinical Studies of Oral Combination Are Expected to Begin in Second Half of 2021.
Gilead Sciences Inc - Co, Merck Will Work As Partners, Sharing Operational Responsibilities, and Development, Commercialization and Marketing Costs.
Gilead Sciences - Across Oral & Injectable Formulation Programs, Co & Merck Will Share Global Development & Commercialization Costs 60%/40%, Respectively.
Gilead Sciences Inc - Gilead and Merck Will Share Global Development and Commercialization Costs 60%/40%, Respectively.
Gilead Sciences - for Long-acting Oral Products, Co Will Lead Commercialization in U.S. and Merck Will Lead Commercialization in Eu and Rest of World.
Gilead Sciences Inc - for Long-acting Oral Products, Co Will Lead Commercialization in U.S., Merck Will Lead Commercialization in Eu, Rest of World.
Gilead Sciences - for Long-acting Injectable Products, Merck to Lead Commercialization in U.S. & Co to Lead Commercialization in Eu and Rest of World.
Gilead Sciences Inc - to Co-develop and Co-commercialize Long-acting Treatments in Hiv That Combine Gilead's Lenacapavir and Merck's Islatravir.